9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors

Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors

Estimated reading time: < 1 min

Condition: Non-myeloablative TCR Alpha/Beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation

Estimated Enrollment: 32

Gender: All

Min Age: 12 Months

Age Group: Child, Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Incidence of adverse events,  Maximum tolerated dose and/or recommended phase 2 dose of cord blood-derived expanded allogeneic natural killer (NK) cells following chemotherapy,  NK cell persistence, phenotype, and function, Response rate per immune-related therapy trials Response Evaluation Criteria in Solid Tumors (irRECIST)

Interventions: Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: December 1, 2022

Completion Date: December 1, 2022

Last  Posted Date: May 20, 2019

Location: M D Anderson Cancer Center, Houston, Texas, United States

Website Link: https://ClinicalTrials.gov/show/NCT03420963

Was this article helpful?
Dislike 0